At Charing Cross, we are listed as providing an Inhibin A assay. I stopped
offering this assay because, in granulosa-cell ovarian cancers, some
Inhibin variants appear to be undetected by the commercial sandwich assays
(A, B & Pro-alpha C) - in an analogous way to hCG. A new, total assay was
being developed in Australia to replace the original broad-spectrum but
insensitive polyclonal competitive "Monash" assay, and this should be
available by the end of the year.
Professor Nigel Groome has now said that the Inhibin B assay should have
the same detection as this total assay for ovarian cancer, and I am now
resuming the availability of the Inhibin B assay. I have stored samples for
all those patients with Inhibin requests and can assay them, but of course
their current relevence is likely to be low.
Can you please pass this information to interestes clinicians.
Hugh Mitchell
Medical Oncology Department, Charing Cross Hospital, LONDON W6 8RF
------ACB discussion List Information--------
This is an open discussion list for the academic and clinical
community working in clinical biochemistry.
Please note, archived messages are public and can be viewed
via the internet. Views expressed are those of the individual and
they are responsible for all message content.
ACB Web Site
http://www.acb.org.uk
List Archives
http://www.jiscmail.ac.uk/lists/ACB-CLIN-CHEM-GEN.html
List Instructions (How to leave etc.)
http://www.jiscmail.ac.uk/
|